[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 7 days · First seen · Last updated

Biotech advancements in cancer research and clinical trials

Overview

VERAXA Biotech has begun implementing New Approach Methodologies (NAMs) in its preclinical research to align with U.S. Food and Drug Administration guidelines and reduce animal testing. The company reported that using an ex vivo panel of patient-derived xenograft models for its BiTAC-based T cell engagers and antibody-drug conjugates required approximately 10 mice, whereas traditional in vivo studies would have required an estimated 200 or more.

Following these developments, VERAXA Biotech presented in vivo proof-of-concept data for its BiTAC-ADC technology platform at the 17th World ADC Congress. In a breast cancer model, a single 3 mg/kg dose resulted in significant tumor regression without a decrease in body weight. In vitro studies indicated the platform can distinguish cancer cells from healthy cells to prevent the release of active toxins outside the tumor, suggesting a potential for reduced off-target systemic toxicity compared to conventional antibody-drug conjugates.

Entities

VERAXA Biotech · World ADC Congress · Thermo Fisher Scientific · Quantum BioPharma · European Molecular Biology Laboratory

Timeline

  1. [TECHNOLOGY] 2 sources
    VERAXA Biotech presents proof-of-concept data for BiTAC-ADC platform

    VERAXA Biotech has validated its BiTAC-ADC platform through in vivo studies, demonstrating significant tumor regression in breast cancer models with reduced potential for off-target toxicity.

  2. [BUSINESS] 2 sources
    Biotech companies advance cancer research methods and MS clinical trials

    VERAXA Biotech is adopting new methodologies to reduce animal testing in cancer research, while Quantum BioPharma partners with Thermo Fisher to begin Phase 2 trials for a multiple sclerosis treatment.

Sources

citybuzz.co · istr.org · tradingview.com